An observational study in Chronic Pelvic Pain, sponsored by SoLa Pelvic Therapy. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.
Sponsored by SoLa Pelvic Therapy · Observational
Among 151 studies in Pelvic Pain with a site in United States — 36 open to participants now, 39 under way, 1 of them phase 3. Pelvic Pain · United States.
Among the 151 studies in Pelvic Pain with a site in United States, this one is the 4th largest by planned enrollment of the 28 observational ones, is one of 14 that started in 2026, is one of 28 observational ones, reaches primary completion later than 33 of the 38 other live ones, and was the 149th registered.
375 studies on the registry are indexed under Pelvic Pain; 89 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 100 across 83 observational studies indexed under Pelvic Pain.
Browse Pelvic Pain studies →36 of the 151 studies in Pelvic Pain with a site in United States are open now, in 1 country. Each count lists the studies.
Of the 59 Pelvic Pain studies recruiting now, 21 (36%) set no upper age limit and 36 (61%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →151 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 14 started in 2026.
Median enrollment 50 across the 123 interventional studies, 104 across the 28 observational. Of the 96 that completed or were terminated, 35 (36%) have results posted.
18 of 151 have an industry lead sponsor. The 10 most frequent:
SoLa Pelvic Therapy is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
SoLa Pelvic Therapy has 2 studies filed under Pelvic Pain — fewer than ten, so there is no comparison to draw.
15 of the studies in Pelvic Pain with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06110065University of ArizonaCT-guided Pudendal Nerve Cryoneurolysis for Palliation of Malignancy-induced Pelvic Pain | 2026-11 |
| NCT05354869University of California, Los AngelesTransvaginal Electrical Stimulation for Myofascial Pelvic Pain | 2026-12 |
| NCT03794466University of Kansas Medical CenterQuantify the Degree of Pain Relief of Pelvic Congestion Syndrome Following Gonadal Vein Embolization | 2026-12-31 |
| NCT06083597Weill Medical College of Cornell UniversityDevelopment of a Patient-reported Outcome Measure for Women With Chronic Pelvic Pain | 2026-12-31 |
| NCT06611501Boston Children's HospitalGlycemic Regulation as Endometriosis Adjunct Treatment | 2027-01 |
Among the 151 studies in Pelvic Pain with a site in United States, from their registry updates:
The VOICE Registry is a multicenter, prospective, observational registry designed to collect real-world data on the clinical use of SoLá Pelvic Therapy® (SPT) in patients with chronic pelvic pain (CPP). The registry will follow patients receiving transvaginal photobiomodulation (PBM) therapy with SPT as part of their standard clinical care. The primary purpose of the registry is to collect real-world evidence on the use and safety of SPT.
The VOICE Registry is a prospective, multicenter, observational registry designed to evaluate the real-world use of transvaginal photobiomodulation with SoLá Pelvic Therapy® in patients with chronic pelvic pain. Participants receive SoLá Pelvic Therapy® as part of their standard clinical care, independently of participation in the registry.
The registry does not assign treatment or dictate clinical management. Decisions regarding patient selection, treatment frequency, treatment regimen, and concomitant therapies remain at the discretion of the treating healthcare professional. Participants are followed for 12 months from initiation of therapy to collect longitudinal information on device utilization, safety, and patient-reported outcomes.
Adults aged 18 years or older who are selected by their treating healthcare professional to receive transvaginal photobiomodulation with SoLá Pelvic Therapy® as part of standard clinical care. Participants are enrolled from routine clinical practice at participating healthcare sites.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Patients will be excluded from the registry only if the treating healthcare professional determines that SoLá Pelvic Therapy® is not appropriate or .
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with chronic pelvic pain receiving SoLá Pelvic Therapy (SPT) as part of routine clinical care. Participants are followed prospectively through the registry to collect treatment, use and safety information.
Device: SoLá Pelvic Therapy (SPT)
SoLá Pelvic Therapy (SPT) is administered as part of routine clinical care to patients with chronic pelvic pain. Treatment is not assigned by the registry. The registry prospectively collects treatment, and safety information from patients receiving SPT at participating sites.
Change in Chronic Pelvic Pain Severity
Change in patient-reported pelvic pain severity following SoLá Pelvic Therapy (SPT), assessed using the Numeric Pain Rating Scale (NPRS), ranging from 0 (no pain) to 10 (worst possible pain). Lower scores indicate less pain.
Time frame: Baseline through 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Apr 2029, 36 months after the start.
Of 33 observational studies under Pelvic Pain, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15. This study's planned 36 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
SoLa Pelvic Therapy